$NTRA

Rabinowitz Matthew sold $196K of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 731 shares of Natera, Inc. (NTRA) at $267.99 ($0.20M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale of 731 shares at $267.9893 on 2026-08-03, with the filing made on 2026-08-05, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 designation generally limits actionable signal for valuation or near-term catalysts.

03

What to watch

The article provides only the sale details and post-transaction holdings; it does not include any concurrent buy activity, guidance changes, or operational updates.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05 for a sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA) by executive chairman Matthew Rabinowitz.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera executive chairman Matthew Rabinowitz sold 731 shares in an open-market transaction for about $195.9K, disclosed via Form 4.

Expected impact

Likely minimal impact on NTRA price; any effect would be short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a routine Form 4 insider transaction and explicitly notes a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, some traders may view insider selling as a mild negative sentiment input, especially if paired with other negative signals not present here.

Key entities

  • Natera, Inc.

    Company whose executive chairman insider sale is disclosed on Form 4.

  • Matthew Rabinowitz

    Executive chairman and reporting person who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.